|
|
 |
|
Viewing report
|
|
|
|
Antivirals: Novel Targets, Technologies, and Dealmaking
Decision Resources, Inc., Feb 2010, Pages: 32
The hottest field in antivirals is hepatitis C virus (HCV) drug development; compounds against novel HCV targets such as NS3/4A protease, NS5B polymerase, and NS5A hold the promise of revolutionizing the treatment of this disease. Targeted antivirals have been enormously successful for human immunodefi ciency virus (HIV) and include life-saving blockbusters such as Truvada, Atripla, Kaletra, and Reyataz. The HIV pharmacopoeia has expanded from drugs that target reverse transcriptase and protease to include inhibitors of CCR5, integrase, and viral fusion. Most HIV drug development is for existing targets, but companies are also investigating novel targets such as viral maturation.
Questions Answered in This Report
- Although no HCV-specific antiviral agents have reached the market, the HCV development pipeline is robust and includes mainly HCV-specific antiviral agents.
Which are the most promising classes for discovery and development of novel targeted HCV drugs? Which development compounds are the most advanced? What companies are involved in HCV antiviral drug development?
- The current HIV pharmacopoeia is rich with drugs that are effective and relatively well tolerated.
What novel target classes show the most promise? What strategies can developers use to gain a competitive advantage? What new technologies may offer new approaches to treating HIV infections?
- Although most development activity is directed at HCV and HIV, other commercial opportunities are available in antivirals.
Which diseases offer the potential for the development of novel classes of agents?
How can new technologies create new opportunities for antivirals? What companies are developing new antiviral technologies?
- Researchers are applying RNA-based therapy technologies, including RNA interference (RNAi), to the development of novel antivirals.
Which companies are developing RNA and RNAi-based antivirals? Which RNA-based technologies are the most advanced in development? Which diseases are likely to benefit from RNAi-based drugs?
- Many drugs in the current pipeline originated at biotech companies.
Which companies are currently conducting innovative antivirals research? (See our comprehensive listing.) What kind of dealmaking has Big Pharma engaged in to tap these early-stage endeavors?
Scope of the report
- Current antiviral drug classes and targets: interferons (IFNs), pegylated IFNs, nucleoside analogues, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), nucleoside polymerase inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, CCR5 inhibitors, fusion inhibitors, integrase inhibitors, neuraminidase inhibitors, monoclonal antibodies (MAbs).
- Hepatitis C virus (HCV): virus and disease, current treatment, novel drug targets, development compounds, companies.
- Human immunodeficiency virus (HIV): virus and disease, current treatment, novel drug targets, development compounds, companies.
- Respiratory syncytial virus (RSV): virus and disease, current treatment, novel drug targets, development compounds, companies.
- Outlook for antiviral drug discovery and development—targeted antivirals, HIV, HCV, RSV, herpes virus, and influenza virus: virus and disease, current treatment, novel drug targets, development compounds, companies.
Customers who bought this item also bought
Antiviral Drugs: From Basic Discovery Through Clinical Trials
Hepatitis C Viral Infection - After Protease Inhibitors What Is Next?
The Global Antivirals Market: R&D Pipelines, Market Analysis and Competitive Landscape
Hepatitis C Virus - Protease Inhibitors Bring Change in the Treatment Paradigm for Hepatitis C Virus Infection - What Next?
The Antivirals Pipeline: Competitive Review
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
Antivirals - Global Strategic Business Report
Anti-Infectives - Global Strategic Business Report
Antiviral Drug Development
Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition
|
|
|
|
